BXL0124

BXL0124 is a **Gemini vitamin D analog**, a synthetic derivative of vitamin D designed to modulate vitamin D receptor (VDR) signaling with minimal calcemic side effects. It acts primarily by binding and activating the **vitamin D receptor (VDR)**, leading to the repression of pro-tumorigenic signaling pathways, particularly **CD44-STAT3 complex formation** and its downstream effects. BXL0124 has shown preclinical efficacy in **inhibiting proliferation, invasion, and tumorigenesis in breast cancer models** by decreasing the expression of invasion markers (like CD44, MMP-2, MMP-9, uPA) and suppressing key oncogenic signaling cascades, including **JAK2/STAT3** and **ErbB2/Her2-downstream signaling**. It is under investigation for its chemopreventive and antitumor effects, notably in **basal-like and ErbB2-positive breast cancers**[1][2][3].

Other names

Gemini vitamin D analog BXL0124